{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T07:29:57Z","timestamp":1787642997205,"version":"build-2736575974"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T00:00:00Z","timestamp":1715817600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Osimertinib has demonstrated efficacy in patients with epidermal growth factor receptor (EGFR) T790M-positive non-small cell lung cancer (NSCLC) in clinical trials. However, real-world data on its effectiveness remain scarce. Taiwanese patients with T790M-positive locally advanced or metastatic NSCLC and progressive disease following treatment with at least one EGFR tyrosine kinase inhibitor (TKI) were enrolled from the osimertinib early access program. Of the 419 patients (mean age, 63 years; female, 67%), 53% were heavily pretreated (\u2265 third-line [3L]), making osimertinib a fourth-line (4L) intervention. The median progression-free survival (PFS) was 10.5 months (95% confidence interval [CI]: 8.95\u201311.41); the 18-month PFS rate was 26.5%. The median overall survival (OS) was 19.0 months (95% CI: 16.30\u201320.95); the 24-month OS rate was 40.9%. The objective response rate was 32.46%, and the disease control rate was 86.38%. The median time to treatment discontinuation of osimertinib monotherapy was 11.9 months (95% CI: 10.49\u201313.11). Subgroup analyses of median PFS and OS in the chemotherapy combination group vs. the osimertinib monotherapy group yielded no difference. Central nervous system (CNS) metastasis, number of prior lines of therapy, and types of initial EGFR-TKIs did not significantly impact outcomes. The median PFS values were 9.0 (95% CI: 5.18\u201311.34) and 10.9 (95% CI: 9.18\u201311.90) months with and without CNS metastasis, respectively, and 10.8 (95% CI: 8.59\u201312.69), 13.6 (95% CI: 10.89\u201316.3), and 9.2 (95% CI: 7.8\u201310.62) months for second-line (2L), 3L, and \u22654L therapy, respectively. In patients who received osimertinib as 2L therapy, the median PFS values in response to prior afatinib, erlotinib and gefitinib treatment were 11.2 (95% CI: 4.85\u20134.79), 10.5 (95% CI: 8.59\u201320.26) and 8.7 (95% CI: 7.21\u201316.79) months, respectively. Overall, real-world data from Taiwan support the clinical benefits of osimertinib in EGFR T790M -positive NSCLC.<\/jats:p>","DOI":"10.1371\/journal.pone.0303046","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T17:46:03Z","timestamp":1715881563000},"page":"e0303046","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer"],"prefix":"10.1371","volume":"19","author":[{"given":"Gee-Chen","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Yuan","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong-Jen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng-Sheng","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1846-1027","authenticated-orcid":true,"given":"Cheng-Ta","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Chung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jen-Yu","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Yen","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Chou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Feng","family":"Chian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Te-Chun","family":"Hsia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0585-8463","authenticated-orcid":true,"given":"Yuh-Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,5,16]]},"reference":[{"key":"pone.0303046.ref001","unstructured":"Taiwan Ministry of Health and Welfare. Causes of death statistics. 2020 [cited 2021 June 16]. https:\/\/dep.mohw.gov.tw\/DOS\/cp-5202-61530-113.html."},{"key":"pone.0303046.ref002","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"D Planchard","year":"2018","journal-title":"Ann Oncol"},{"key":"pone.0303046.ref003","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Y Shi","year":"2014","journal-title":"J Thorac Oncol"},{"key":"pone.0303046.ref004","doi-asserted-by":"crossref","first-page":"e28204","DOI":"10.1371\/journal.pone.0028204","article-title":"Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers","volume":"6","author":"C Li","year":"2011","journal-title":"PLoS One"},{"key":"pone.0303046.ref005","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2014.104","article-title":"Acquired resistance to TKIs in solid tumours: learning from lung cancer","volume":"11","author":"DR Camidge","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"pone.0303046.ref006","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer","volume":"4","author":"DA Cross","year":"2014","journal-title":"Cancer Discov"},{"issue":"Suppl 5","key":"pone.0303046.ref007","doi-asserted-by":"crossref","first-page":"V116","DOI":"10.1093\/annonc\/mdq189","article-title":"Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"21","author":"G D\u2019Addario","year":"2010","journal-title":"Ann Oncol"},{"key":"pone.0303046.ref008","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00280-011-1632-x","article-title":"Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation","volume":"68","author":"G Metro","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"pone.0303046.ref009","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s12094-015-1297-8","article-title":"Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations","volume":"17","author":"T Masuda","year":"2015","journal-title":"Clin Transl Oncol"},{"key":"pone.0303046.ref010","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.2011.41.2056","article-title":"First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial","volume":"30","author":"C Gridelli","year":"2012","journal-title":"J Clin Oncol"},{"key":"pone.0303046.ref011","doi-asserted-by":"crossref","first-page":"630","DOI":"10.4143\/crt.2014.244","article-title":"Pemetrexed singlet versus nonpemetrexed-based platinum doublet as second-line chemotherapy after first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor failure in non-small cell lung cancer patients with EGFR mutations","volume":"47","author":"S Park","year":"2015","journal-title":"Cancer Res Treat"},{"key":"pone.0303046.ref012","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"PA J\u00e4nne","year":"2015","journal-title":"N Engl J Med"},{"key":"pone.0303046.ref013","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/S1470-2045(16)30508-3","article-title":"Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study","volume":"17","author":"G Goss","year":"2016","journal-title":"Lancet Oncol"},{"key":"pone.0303046.ref014","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2016.70.3223","article-title":"Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component","volume":"35","author":"JC Yang","year":"2017","journal-title":"J Clin Oncol"},{"key":"pone.0303046.ref015","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/cncr.31891","article-title":"Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: long-term follow-up from a pooled analysis of 2 phase 2 studies","volume":"125","author":"MJ Ahn","year":"2019","journal-title":"Cancer"},{"key":"pone.0303046.ref016","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer","volume":"376","author":"TS Mok","year":"2017","journal-title":"N Engl J Med"},{"key":"pone.0303046.ref017","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.2217\/fon-2020-0203","article-title":"Real-world osimertinib for EGFR mutation-positive non-small-cell lung cancer with acquired T790M mutation","volume":"16","author":"F Imamura","year":"2020","journal-title":"Future Oncol"},{"key":"pone.0303046.ref018","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/1759-7714.13378","article-title":"Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: a retrospective multicenter study of its real-world efficacy and safety in advanced\/recurrent non-small cell lung carcinoma","volume":"11","author":"T Kishikawa","year":"2020","journal-title":"Thorac Cancer"},{"key":"pone.0303046.ref019","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1007\/s00432-018-2754-x","article-title":"Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer","volume":"144","author":"JA Stratmann","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"pone.0303046.ref020","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.lungcan.2018.11.037","article-title":"Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation","volume":"127","author":"JB Auliac","year":"2019","journal-title":"Lung Cancer"},{"key":"pone.0303046.ref021","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.2217\/fon-2019-0324","article-title":"ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer","volume":"15","author":"F Marinis","year":"2019","journal-title":"Future Oncol"},{"key":"pone.0303046.ref022","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.4143\/crt.2017.460","article-title":"Intercalated treatment following rebiopsy is associated with a shorter progression-free survival of osimertinib treatment","volume":"50","author":"JS Tseng","year":"2018","journal-title":"Cancer Res Treat"},{"key":"pone.0303046.ref023","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejca.2021.02.019","article-title":"Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: an open-label, randomised phase 2 clinical trial","volume":"149","author":"K Tanaka","year":"2021","journal-title":"Eur J Cancer"},{"key":"pone.0303046.ref024","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"JC Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"pone.0303046.ref025","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"SS Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"pone.0303046.ref026","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jtho.2018.09.004","article-title":"Osimertinib versus standard of care EGFR TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA Asian subset","volume":"14","author":"BC Cho","year":"2019","journal-title":"J Thorac Oncol"},{"key":"pone.0303046.ref027","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.3892\/ol.2020.11801","article-title":"Patients with advanced non-small cell lung cancer with EGFR mutations in addition to complex mutations treated with osimertinib have a poor clinical outcome: a real-world data analysis","volume":"20","author":"N Chang","year":"2020","journal-title":"Oncol Lett"},{"key":"pone.0303046.ref028","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.2018.77.9363","article-title":"CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3)","volume":"36","author":"YL Wu","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0303046","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T17:46:22Z","timestamp":1715881582000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0303046"}},"subtitle":[],"editor":[{"given":"Chien-Feng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,5,16]]},"references-count":28,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0303046","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,16]]}}}